Association between sarcopenia level and metabolic syndrome

Area of Science:

• Gerontology
• Metabolic Health
• Cardiovascular Health

Background:

• Metabolic syndrome (MetS) significantly elevates risks for diabetes mellitus (DM), cardiovascular disease (CVD), cancer, and mortality.
• Sarcopenia, characterized by age-related muscle loss, is increasingly recognized as a risk factor for MetS, non-alcoholic fatty liver disease, and CVD.

Purpose of the Study:

• To investigate the association between sarcopenia and the prevalence of MetS.
• To analyze the dose-response relationship between skeletal muscle mass and MetS prevalence.

Main Methods:

• 13,620 participants were analyzed from October 2014 to December 2019.
• Skeletal muscle mass was quantified using bioelectrical impedance analysis (BIA), with appendicular skeletal muscle mass (ASM) expressed as a percentage of body weight (ASM%).
• Linear and logistic regression analyses, adjusted for multiple covariates, were employed to assess the relationship between ASM% quartiles and MetS risk.

Main Results:

• A significant dose-response relationship was observed between ASM% and MetS prevalence.
• Sarcopenia was independently associated with an increased prevalence of MetS, even after adjusting for age, sex, obesity, hypertension (HT), DM, dyslipidemia (DL), smoking, alcohol intake, and C-reactive protein (CRP).
• Each 1-quartile increment in ASM% was associated with a 25% decrease in the risk of MetS (P < 0.001).

Conclusions:

• Sarcopenia, as measured by BIA, is an independent risk factor for MetS.
• A clear dose-response relationship exists between skeletal muscle mass and the prevalence of MetS.